 Virpax Pharmaceuticals Inc NASDAQ: VRPX is surging higher Tuesday after the company announced that it received a written pre-investigational new drug response from the U.S. Food and Drug Administration for MMS019. MMS019 is Virpax Pharmaceuticals patented and proprietary high-density molecular masking spray under development for use as an anti-viral barrier product. 